To determine the impact of Regorafenib on tumor-associated macrophages in vivo, we evaluated the murine macrophage marker F4/80 as well as CSF1R expression in the pancreata of Regorafenib- and PEG-treated mice by immunohistochemistry. Here, CSF1R is linked to neoplasm.